Dimensional Fund Advisors
ACRV icon

Dimensional Fund Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Dimensional Fund Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$94.7K Buy
46,188
+16,856
+57% +$32.1K ﹤0.01% 3137
2026
Q2 		$52.2K Buy
29,332
+10,968
+60% +$18.6K ﹤0.01% 3188
2026
Q1 		$25.4K Hold
18,364
– – ﹤0.01% 3200
2025
Q4 		$44.3K Sell
18,364
-1,215
-6% -$2.64K ﹤0.01% 3216
2025
Q3 		$35.5K Sell
19,579
-2,625
-12% -$3.69K ﹤0.01% 3252
2025
Q2 		$26.4K Sell
22,204
-21,950
-50% -$30.1K ﹤0.01% 3261
2025
Q1 		$90K Buy
44,154
+7,091
+19% +$38.2K ﹤0.01% 3212
2024
Q4 		$223K Buy
37,063
+6,239
+20% +$45.3K ﹤0.01% 3146
2024
Q3 		$216K Buy
30,824
+20,758
+206% +$164K ﹤0.01% 3157
2024
Q2 		$58.4K Buy
+10,066
New +$81.1K ﹤0.01% 3298

Other funds holding ACRV

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
AAF Wealth Management
AAF Wealth Management Westborough, Massachusetts $275M AUM 17.17% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Redwood Park Advisors
Redwood Park Advisors Redwood City, California $157M AUM 7.34% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Dimensional Fund Advisors's ACRV Position: Q3 2026 in Review

Dimensional Fund Advisors increased its Acrivon Therapeutics (ACRV) stake by 57% in Q3 2026, buying an estimated $32.1K and bringing the position to 46,188 shares worth $94.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3137.

Dimensional Fund Advisors first reported a position in ACRV in Q2 2024 and has held it in 10 quarters since. The position peaked at $223K in Q4 2024. 11 funds tracked by Wall St. Rank hold ACRV as of Q3 2026.

  • Dimensional Fund Advisors held 46,188 shares of Acrivon Therapeutics worth $94.7K as of Q3 2026.
  • Dimensional Fund Advisors bought 16,856 Acrivon Therapeutics shares in Q3 2026, an estimated $32.1K.
  • Acrivon Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #3137 holding.
  • Dimensional Fund Advisors first reported a position in Acrivon Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • Dimensional Fund Advisors's Acrivon Therapeutics position peaked at $223K in Q4 2024.
  • 11 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.